Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.53 |
| ▸ | HTR3B | O95264 | 2/20 | 0.53 |
| ▸ | HTR3A | P46098 | 2/20 | 0.53 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.53 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.53 |
| ▸ | PLAU | P00749 | 2/20 | 0.53 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.53 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.53 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | NOS3 | P29474 | 4/20 | 0.46 |
| ▸ | NOS1 | P29475 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL662014 | 0.90 | PLAU (0.47) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL4516878 | 0.86 | HTR3E (0.51) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL4517019 | 0.86 | RAB9A (0.55) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL29478736 | 0.79 | USP2 (0.65) | RAB9ANPC1HPGDCASP3SENP7 | |
| SCHEMBL101868 | 0.79 | USP2 (0.65) | RAB9ANPC1HPGDCASP3SENP7 | |
| SCHEMBL101867 | 0.79 | USP2 (0.65) | RAB9ANPC1HPGDCASP3SENP7 | |
| SCHEMBL21379771 | 0.73 | HTR3E (0.52) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL21379768 | 0.73 | HTR3E (0.52) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL11771956 | 0.73 | CYP2D6 (0.56) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL4100900 | 0.71 | HTR3E (1.00) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729101-B2 | 1H-imidazole derivative having CB1, agonistic, CB1 partial agonistic or CB1 antagnistic activity | SOLVAY PHARMACEUTICALS, B.V. (NL) | 2014-05-20 | — | — | US | disclosed |
| CN-101538244-A | 1H-imidazole derivatives with CB1agonistic, CB1partial agonistic or CB1antagonistic activities | SOLVAY PHARM BV (NL) | 2009-09-23 | — | — | CN | disclosed |
| US-20090181949-A1 | 1H-IMIDAZOLE DERIVATIVE HAVING CB1, AGONISTIC, CB1 PARTIAL AGONISTIC OR CB1 ANTAGNISTIC ACTIVITY | SOLVAY PHARMACEUTICALS B.V. | 2009-07-16 | — | — | US | disclosed |
| US-7495108-B2 | Imidazoline derivatives having CB1-antagonistic activity | SOLVAY PHARMACEUTICALS, B.V. | 2009-02-24 | — | — | US | disclosed |
| EP-1438296-B1 | 1H-IMIDAZOLE DERIVATIVES HAVING CB1 AGONISTIC, CB1 PARTIAL AGONISTIC OR CB1- ANTAGONISTIC ACTIVITY | SOLVAY PHARM BV (NL) | 2008-11-26 | — | — | EP | disclosed |
| EP-1725536-B1 | IMIDAZOLINE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | SOLVAY PHARM BV (NL) | 2008-10-15 | — | — | EP | disclosed |
| US-20070135492-A1 | Imidazoline derivatives having CB1-antagonistic activity | SOLVAY PHARMACEUTICALS, B.V,. | 2007-06-14 | — | — | US | disclosed |
| US-7173044-B2 | Imidazoline derivatives having CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2007-02-06 | — | — | US | disclosed |
| EP-1725536-A2 | IMIDAZOLINE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | Solvay Pharmaceuticals B.V. (NL) | 2006-11-29 | — | — | EP | disclosed |
| US-20060241152-A9 | Imidazoline derivatives having CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. | 2006-10-26 | — | — | US | disclosed |
| WO-2005099705-A2 | PREPARATION OF IMIDAZOLE DERIVATIVES AND METHODS OF USE | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-10-27 | — | — | WO | disclosed |
| WO-2005080345-A2 | IMIDAZOLINE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-09-01 | — | — | WO | disclosed |
| US-20050187259-A1 | Imidazoline derivatives having CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. | 2005-08-25 | — | — | US | disclosed |
| US-20050054679-A1 | 1 H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. | 2005-03-10 | — | — | US | disclosed |
| US-20040235854-A1 | 1H-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1 antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2004-11-25 | — | — | US | disclosed |
| EP-1438296-A2 | 1H-IMIDAZOLE DERIVATIVES HAVING CB1 AGONISTIC, CB1 PARTIAL AGONISTIC OR CB1- ANTAGONISTIC ACTIVITY | Solvay Pharmaceuticals B.V. (NL) | 2004-07-21 | — | — | EP | disclosed |
| EP-1432691-A1 | IMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF FOR TREATMENT OF OBESITY | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20040063691-A1 | Preparation and use of imidazole derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-04-01 | — | — | US | disclosed |
| WO-2003040107-A1 | IMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF FOR TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-05-15 | — | — | WO | disclosed |
| WO-2003027076-A2 | 1H-IMIDAZOLE DERIVATIVES HAVING CB1 AGONISTIC, CB1 PARTIAL AGONISTIC OR CB1- ANTAGONISTIC ACTIVITY | SOLVAY PHARMACEUTICALS B.V. (NL) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181949-A1 | 1H-IMIDAZOLE DERIVATIVE HAVING CB1, AGONISTIC, CB1 PARTIAL AGONISTIC OR CB1 ANTAGNISTIC ACTIVITY | CNR1, CNR2, CHRM1 | HTR3E 434/4885HTR3B 290/4885HTR3A 316/4885 |
| US-20070135492-A1 | Imidazoline derivatives having CB1-antagonistic activity | CNR2, CNR1, GRIN2C | HTR3E 203/4885HTR3B 90/4885HTR3A 121/4885 |
| US-20050187259-A1 | Imidazoline derivatives having CB1-antagonistic activity | CNR2, CNR1, GRIN2C | HTR3E 206/4885HTR3B 95/4885HTR3A 116/4885 |
| US-20040063691-A1 | Preparation and use of imidazole derivatives for treatment of obesity | GPR119, GIPR, PGC | HTR3E 201/4885HTR3B 114/4885HTR3A 466/4885 |
| US-20060241152-A9 | Imidazoline derivatives having CB1-antagonistic activity | CNR2, CNR1, GRIN2C | HTR3E 206/4885HTR3B 95/4885HTR3A 116/4885 |
| US-20040235854-A1 | 1H-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1 antagonistic activity | CNR1, CNR2, CHRM1 | HTR3E 277/4885HTR3B 166/4885HTR3A 194/4885 |
| US-20050054679-A1 | 1 H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity | CNR1, CNR2, HRH4 | HTR3E 177/4885HTR3B 124/4885HTR3A 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.